{
    "paper_id": "PMC7161908",
    "metadata": {
        "title": "Care of haematology patients in a COVID\u201019 epidemic",
        "authors": [
            {
                "first": "John",
                "middle": [],
                "last": "Willan",
                "suffix": "",
                "email": "john.willan@nhs.net",
                "affiliation": {}
            },
            {
                "first": "Andrew",
                "middle": [
                    "J."
                ],
                "last": "King",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Sandy",
                "middle": [],
                "last": "Hayes",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Graham",
                "middle": [
                    "P."
                ],
                "last": "Collins",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Andrew",
                "middle": [],
                "last": "Peniket",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Contact details of all patients, including e\u2010mail address and mobile telephone number, should be confirmed and strategies developed to enable rapid updates of the patient population en masse with the latest advice via e\u2010mail and/or text. Patients should be advised that normal communication channels may be unavailable depending upon staff capacity.",
            "cite_spans": [],
            "section": "Communication and remote working",
            "ref_spans": []
        },
        {
            "text": "Healthcare workers and administrators should be provided with Information Technology (IT) support to enable them to work remotely, such that they can continue to work if fit but self\u2010isolating, or if not required to be on site.",
            "cite_spans": [],
            "section": "Communication and remote working",
            "ref_spans": []
        },
        {
            "text": "Self\u2010isolation may enable patients to delay, or avoid, infection by COVID\u201019, and this may be of critical importance, particularly following chemotherapy. As the number of cases in the community and hospitals rise, so will the risks to the patient of leaving their home to attend clinic appointments. Bringing potentially immunosuppressed, and often elderly, patients with cancer into this environment should be avoided where possible. Outpatient clinics should move to telephone appointments or video\u2010conferencing arrangements wherever this is felt to be acceptable.",
            "cite_spans": [],
            "section": "Outpatient clinics",
            "ref_spans": []
        },
        {
            "text": "Patients attending in person could be asked to wait in their car until the clinician is available to see them, reducing their exposure to other patients.",
            "cite_spans": [],
            "section": "Outpatient clinics",
            "ref_spans": []
        },
        {
            "text": "Clustering large groups of vulnerable and potentially unwell patients into waiting areas for phlebotomy has the potential to facilitate the spread of the infection. Consideration should be given to extending the interval between monitoring blood tests, as the risks, and burdens on the health service of their provision increases.",
            "cite_spans": [],
            "section": "Phlebotomy",
            "ref_spans": []
        },
        {
            "text": "The establishment of off\u2010site phlebotomy facilities, e.g. in car parks, where patients can queue within their cars, would minimise their contact with other patients.",
            "cite_spans": [],
            "section": "Phlebotomy",
            "ref_spans": []
        },
        {
            "text": "Routine, in hospital, provision of supportive treatments aimed at minimising longer term side\u2010effects should be paused. Such treatments would include: the use of bisphosphonates to reduce skeletal\u2010related events in patients with myeloma, venesection to reduce iron burden in patients after allogeneic transplant or in selected patients with erythrocytosis and hereditary haemochromatosis. Therapies that can easily be paused should be nationally agreed and circulated.",
            "cite_spans": [],
            "section": "Supportive treatments delivered in a hospital setting",
            "ref_spans": []
        },
        {
            "text": "Individualised decisions on the benefits and risks of continuation of maintenance chemotherapy will have to be taken if the infection rates in the community rise. The benefit of tight disease control should be balanced against the immunosuppressive effects of the treatment, and the theoretical increased risk of harm from COVID\u201019 that this may carry. Examples where treatment could be deferred may include maintenance rituximab in follicular and mantle cell lymphoma. Ideally, oral chemotherapy should be used where possible to avoid unnecessary hospital visits.",
            "cite_spans": [],
            "section": "Maintenance and non\u2010curative chemotherapy",
            "ref_spans": []
        },
        {
            "text": "If pressures on hospitals increase, and rates of community infection climb, the balance in favour of delaying or abandoning cycles of chemotherapy will increase, to such an extent that, in the worst\u2010case scenario, only immediately life\u2010saving chemotherapy may be considered. This problem may be exacerbated by potential absence due to illness amongst the pool of specialist nurses trained to deliver chemotherapy. Life\u2010saving chemotherapy that will continue should be nationally agreed to ensure equity amongst patients.",
            "cite_spans": [],
            "section": "Curative chemotherapy",
            "ref_spans": []
        },
        {
            "text": "In the case of widespread community infection and substantial pressures on hospitals, it will be hard to justify the prolonged immunosuppression, close follow\u2010up and additional demands on hospital services that come with performing allogeneic (and to a lesser extent, autologous) bone marrow transplants. In this scenario, it is plausible that many transplants will have to be deferred. It may be necessary to ration transplants, and arrange for transfer of patients to areas with sufficient capacity to support delivery and recovery from these regimes. Close liaison amongst the transplant community nationally will be vital.",
            "cite_spans": [],
            "section": "Bone marrow transplantation",
            "ref_spans": []
        },
        {
            "text": "The appropriate management and deferral of planned transplant recipients and donors who have had, or been exposed to, COVID\u201019 has been covered in pragmatic guidelines by the European Society for Blood and Bone Marrow Transplantation and will be updated as new evidence emerges (https://www.ebmt.org/ebmt/news/ebmt-recommendation-coronavirus-disease-covid-19).",
            "cite_spans": [],
            "section": "Bone marrow transplantation",
            "ref_spans": []
        },
        {
            "text": "If community spread increases then relatives and friends should be discouraged from visiting inpatients, and from accompanying patients to clinic appointments; it may prove necessary to strictly enforce this.",
            "cite_spans": [],
            "section": "Visitors",
            "ref_spans": []
        },
        {
            "text": "Due to the global nature of this infection outbreak, it is possible that pathways of drug manufacture may be compromised, and shortages of medicines may develop. Co\u2010ordination of response to this will require national oversight.",
            "cite_spans": [],
            "section": "Provision of medicines",
            "ref_spans": []
        },
        {
            "text": "To reduce potential viral exposure at pharmacy departments, consideration should be given to the use of a drive\u2010through medicine collection facility, where patients are alerted by telephone when their medicine is available. Some hospitals may alternatively choose a courier service.",
            "cite_spans": [],
            "section": "Provision of medicines",
            "ref_spans": []
        },
        {
            "text": "Hospitals should ensure that consideration is given to maintaining functional healthcare systems during periods of high workforce absence due to infection, and the potential consequences of disruption to schools and transport links. The UK Government has proposed drafting in volunteers, and recently retired medical personnel. It may prove necessary to re\u2010deploy haematologists outside of their sub\u2010speciality interest to maintain core services.",
            "cite_spans": [],
            "section": "Workforce",
            "ref_spans": []
        },
        {
            "text": "There is great uncertainty surrounding the burden that managing COVID\u201019 will place on global healthcare systems. It is prudent to plan for a scenario of maximal disruption, and consider how this would affect haematology patients, and the departments managing them, in the hope that many of the measures outlined may not need to be implemented.",
            "cite_spans": [],
            "section": "Summary",
            "ref_spans": []
        },
        {
            "text": "Clear guidance and communication from governments and hospital leaders regarding COVID\u201019 will be essential. In addition, strong leadership within haematology teams nationally and locally will be needed to ensure timely and proportionate implementation of contingency plans, which balance risks and protect patients as infections rise.",
            "cite_spans": [],
            "section": "Summary",
            "ref_spans": []
        },
        {
            "text": "No authors have relevant disclosures to declare.",
            "cite_spans": [],
            "section": "Disclosures",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Covid\u201019 \u2014 Navigating the Uncharted",
            "authors": [],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMe2002387"
                ]
            }
        },
        "BIBREF1": {
            "title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID\u201019) outbreak in China",
            "authors": [],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.2648"
                ]
            }
        },
        "BIBREF2": {
            "title": "Clinical characteristics of coronavirus disease 2019 in China",
            "authors": [],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2002032"
                ]
            }
        },
        "BIBREF3": {
            "title": "Cancer patients in SARS\u2010CoV\u20102 infection: a nationwide analysis in China",
            "authors": [],
            "year": 2020,
            "venue": "Lancet Oncol",
            "volume": "21",
            "issn": "",
            "pages": "335-7",
            "other_ids": {
                "DOI": []
            }
        }
    }
}